Pathoquest
Paris, FR · Founded 2010 · 60 employees on LinkedIn · 2 known investors
PathoQuest is a contract research organization offering GMP-validated next-generation sequencing (NGS) quality control assays under its iDTECT brand for viral safety testing and genetic characterization of biopharmaceuticals. It serves global and emerging biopharma companies working on modalities such as monoclonal antibodies, viral vectors, cell therapies, vaccines, and RNA products, providing an animal-free alternative to traditional in vivo biosafety testing.</parameter> <parameter name="founders">[]
Investors · 2
.jpeg){kind=logo}
Frequently asked questions
- What does Pathoquest do?
- PathoQuest is a contract research organization offering GMP-validated next-generation sequencing (NGS) quality control assays under its iDTECT brand for viral safety testing and genetic characterization of biopharmaceuticals. It serves global and emerging biopharma companies working on modalities such as monoclonal antibodies, viral vectors, cell therapies, vaccines, and RNA products, providing an animal-free alternative to traditional in vivo biosafety testing.</parameter> <parameter name="founders">[]
- Who are Pathoquest's investors?
- Pathoquest's investors include Kurma Partners, Verve Ventures.
- Where is Pathoquest headquartered?
- Pathoquest is headquartered in Paris, FR.